Urgently reviewing AstraZeneca COVID-19 vaccine trial data, says Britain medical regulator

Published On 2020-09-11 03:15 GMT   |   Update On 2020-09-11 03:15 GMT

UK: Britain's medical regulator said on Wednesday it is urgently reviewing information available to determine whether AstraZeneca AZN.L can restart trials of its experimental coronavirus vaccine after an unexplained illness in a participant.In an email, director of licensing at the Medicines and Healthcare products Regulatory Agency (MHRA) Siu Ping Lam said the regulator is working with...

Login or Register to read the full article

UK: Britain's medical regulator said on Wednesday it is urgently reviewing information available to determine whether AstraZeneca AZN.L can restart trials of its experimental coronavirus vaccine after an unexplained illness in a participant.

In an email, director of licensing at the Medicines and Healthcare products Regulatory Agency (MHRA) Siu Ping Lam said the regulator is working with the Oxford Vaccine Centre to review the safety data, in line with protocol for the trial.

"We are urgently reviewing all the information and actively engaging with the researchers to determine whether the trial should restart as quickly as possible," he said.

Participant safety in any clinical trial is a top priority, he said. AstraZeneca is developing the potential vaccine with the University of Oxford.

Read also: Suspension of Covishield trials in UK spells havoc for Astrazeneca and Serum Institute of India

Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News